Sumitomo Mitsui Trust Holdings, Inc. Exelixis, Inc. Transaction History

Sumitomo Mitsui Trust Holdings, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 19, 2024	SELL	$20.17 - $23.93 $29,125 - $34,554	-1,444 Reduced 2.42%	58,296 $1.38 Million
Q4 2023 Jan 30, 2024	BUY	$19.25 - $24.13 $1.15 Million - $1.44 Million	59,740 New	59,740 $1.43 Million
Q4 2022 Jan 30, 2023	SELL	$14.96 - $17.39 $761,987 - $885,759	-50,935 Reduced 59.85%	34,170 $548,000
Q3 2022 Oct 21, 2022	BUY	$15.68 - $22.27 $120,736 - $171,479	7,700 Added 9.95%	85,105 $1.33 Million
Q2 2022 Jul 26, 2022	BUY	$17.44 - $23.16 $199,897 - $265,459	11,462 Added 17.38%	77,405 $1.61 Million
Q1 2022 Apr 27, 2022	BUY	$17.03 - $22.67 $1.12 Million - $1.49 Million	65,943 New	65,943 $1.5 Million

503

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Sumitomo Mitsui Trust Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Sumitomo Mitsui Trust Holdings, Inc. with notifications on news.